Ali Cahid Civelek
Overview
Explore the profile of Ali Cahid Civelek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
404
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Tian M, Zuo C, Civelek A, Carrio I, Watanabe Y, Kang K, et al.
Phenomics
. 2023 Aug;
3(4):375-389.
PMID: 37589025
Alzheimer's disease (AD) is the main cause of dementia, with its diagnosis and management remaining challenging. Amyloid positron emission tomography (PET) has become increasingly important in medical practice for patients...
3.
Zhang X, Jiang H, Wu S, Wang J, Zhou R, He X, et al.
Phenomics
. 2023 Mar;
2(2):102-118.
PMID: 36939797
Positron emission tomography (PET) represents molecular imaging for non-invasive phenotyping of physiological and biochemical processes in various oncological diseases. PET imaging with F-fluorodeoxyglucose (F-FDG) for glucose metabolism evaluation is the...
4.
Patel M, Jha A, Ling A, Chen C, Millo C, Kuo M, et al.
Cancers (Basel)
. 2022 Aug;
14(16).
PMID: 36010880
The study identifies the importance of positron emission tomographic (PET) and anatomic imaging modalities and their individual performances in detecting succinate dehydrogenase A (-related metastatic pheochromocytoma and paraganglioma (PPGL). The...
5.
Jha A, Patel M, Carrasquillo J, Chen C, Millo C, Maass-Moreno R, et al.
J Nucl Med
. 2022 May;
63(9):1300-1301.
PMID: 35618479
No abstract available.
6.
Jha A, Patel M, Carrasquillo J, Ling A, Millo C, Saboury B, et al.
AJR Am J Roentgenol
. 2021 Aug;
218(2):342-350.
PMID: 34431366
. Recent professional society guidelines for radionuclide imaging of sporadic pheochromocytoma (PHEO) recommend F-fluorodihydroxyphenylala-nine (F-FDOPA) as the radiotracer of choice, deeming Ga-DOTATATE and FDG to be second- and third-line agents,...
7.
Luna L, Meleki Z, Shanechi A, Yedavalli V, Civelek A
Clin Nucl Med
. 2021 Jul;
47(1):e26-e28.
PMID: 34284471
A 49-year-old woman from Cameroon presented with history of several months of worsening headache, lethargy, left arm weakness, and generalized lymphadenopathy. Brain MRI demonstrated multifocal signal abnormality and enhancement involving...
8.
Civelek A, Niglio S, Malayeri A, Lin J, Gurram S, Chalfin H, et al.
Urol Oncol
. 2021 Jun;
39(11):787.e17-787.e21.
PMID: 34140245
Objective: Metastatic bladder cancer is an aggressive disease that can often be difficult to diagnose and stage with conventional cross-sectional imaging. The primary objective of this study was to determine...
9.
Nikpanah M, Paschall A, Ahlman M, Civelek A, Farhadi F, Mirmomen S, et al.
Abdom Radiol (NY)
. 2021 Mar;
46(7):3301-3308.
PMID: 33688985
Purpose: To assess differences in FDG-PET/CT uptake among four subtypes of renal tumors: clear cell RCC (ccRCC), papillary type I and II RCC (pRCC), and oncocytoma. Methods: This retrospective study...
10.
Jha A, Taieb D, Carrasquillo J, Pryma D, Patel M, Millo C, et al.
Clin Cancer Res
. 2021 Mar;
27(11):2989-2995.
PMID: 33685867
Targeted radionuclide therapies (TRT) using I-metaiodobenzylguanidine (I-MIBG) and peptide receptor radionuclide therapy (Lu or Y) represent several of the therapeutic options in the management of metastatic/inoperable pheochromocytoma/paraganglioma. Recently, high-specific-activity-I-MIBG therapy...